Status and phase
Conditions
Treatments
About
To demonstrate the safety, pharmacokinetics and pharmacodynamics of drug candidate.
Full description
The study was terminated on June 19, 2009. Decision to terminate was based on Cohort 1 related safety concerns. An alternative clinical design was envisaged to better assess the benefit to risk.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
10 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal